"Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. "@en . "Rilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout. "@en . "8.6 days"@en . "interleukin-1 (IL-1) trap"@en . . "# Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP: Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23031624 # Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V: Role of Interleukin-1 Inhibitors in the Management of Gout. Pharmacotherapy. 2013 Apr 3. doi: 10.1002/phar.1265. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23553601 # Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003 Jun 19;348(25):2583-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12815153 # Cronstein BN, Sunkureddi P: Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013 Jan;19(1):19-29. doi: 10.1097/RHU.0b013e31827d8790. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23319019"@en . . . "CAPS refer to rare genetic syndromes generally caused by mutations in the NLRP-3 [Nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndtrome-1 [CIAS1]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally affected. Fever, urticaria-like rash, arthralgia, myalgia, fatigue, and conjunctivitis are features common to all disorders. In most cases, inflammation in CAPS is associated with mutations in the NLRP-3 gene which encodes the protein cryopyrin, an important component of the inflammasome. Cryopyrin regulates the protease caspase-1 and controls the activation of interleukin-1 beta (IL-1\u03B2). Mutations in NLRP-3 result in an overactive inflammasome resulting in excessive release of activated IL-1\u03B2 that drives inflammation. Rilonacept blocks IL-1\u03B2 signaling by acting as a soluble decoy receptor that binds IL-1\u03B2 and prevents its interaction with cell surface receptors. Rilonacept also binds IL-1\u03B1 and IL-1 receptor antagonist (IL-1ra) with reduced affinity. By binding IL-1, rilonacept prevents the activation of IL-1 receptors, thus reducing inflammatory responses and other effects related to an excess of IL-1."@en . . . . "501081-76-1"@en . . . . " "@en . "Humans and other mammals"@en . . . . "Arcalyst"@en . . "approved"@en . . "Rilonacept"@en . . "Rilonacept is expressed in recombinant Chinese hamster ovary (CHO) cells. "@en .